dallas semaglutide gastric stasis lawyer in Dallas Hammer dallas semaglutide gastric stasis legal

About the SELECT Trial 7 SELECT was a randomized, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for prevention of major adverse cardiovascular outcomes (MACE) in people with established cardiovascular disease with overweight or obesity with no prior history of diabetes

Side effects during the first week at 1.0 mg can be more noticeable than previous increases

and a 44% decreased risk of death

Medicare does not cover any obesity medications and only some Medicaid plans do, while both Medicare and Medicaid cover type 2 diabetes medications like Ozempic